Tricuspid valve disease: diagnosis, prognosis and management of a rapidly evolving field

Lluis Asmarats,Maurizio Taramasso,Josep Rodés-Cabau

DOI: https://doi.org/10.1038/s41569-019-0186-1

IF: 49.421

2019-04-15

Nature Reviews Cardiology

Abstract:Tricuspid valve disease, and particularly tricuspid regurgitation, is a highly prevalent condition with a complex pathophysiology and long-term adverse consequences. Although historically neglected, tricuspid valve disease has gained increasing recognition, with important advances in the assessment and management of this disorder over the past 2 decades. Surgical treatment remains the standard of care, but it continues to have one of the the highest death rates among all cardiac valve-related procedures, and a broad range of patients still do not receive effective therapy for tricuspid valve disease in contemporary clinical practice. Therefore, several alternative, less-invasive technologies for treating patients with severe, native tricuspid valve disease at high surgical risk have been developed in the past decade, with promising early results. This Review summarizes key findings and highlights the latest developments in the diagnosis and management framework that are transforming clinical practice in the complex field of tricuspid valve disease.

cardiac & cardiovascular systems

What problem does this paper attempt to address?

The main problems that this paper attempts to solve are the diagnosis, prognosis, and management of tricuspid valve diseases (especially tricuspid regurgitation). Specifically, the paper focuses on the following aspects:

1. **Limitations of surgical treatment**:
- Although surgery remains the treatment standard for severe tricuspid valve diseases, it has a high in - hospital mortality rate and postoperative complication rate, leading to longer hospital stays and increased medical costs.
- Many patients, due to their severe conditions and long - term lack of effective treatment, are often accompanied by complications such as coagulation disorders, liver failure, advanced kidney disease, and end - stage chronic heart failure, further increasing the surgical risk.

2. **Development of new interventional treatments**:
- With the continuous in - depth understanding of the complex structure of the tricuspid valve and its pathophysiological mechanisms, and more and more evidence showing the negative impact of unrepaired severe tricuspid regurgitation on long - term prognosis, many new transcatheter tricuspid valve interventional (TTVI) techniques have emerged in recent years.
- These new techniques provide alternative treatment options for patients with high surgical risks and have shown early feasibility and safety.

3. **Improvement of clinical evaluation and imaging examinations**:
- In order to better select patients suitable for surgery or interventional treatment, it is necessary to improve the clinical evaluation and imaging examination methods for tricuspid regurgitation.
- Multi - modal imaging techniques and new quantification methods are helpful for more accurately assessing the severity of tricuspid regurgitation, thereby improving the treatment effect.

4. **Natural history and prognosis**:
- The "insidious" course of tricuspid regurgitation once led to its being overlooked, and patients often received treatment only when obvious symptoms appeared, at which time the right heart function had been severely affected.
- There is evidence that clinically significant tricuspid regurgitation is associated with long - term poor prognosis, including higher mortality and incidence of heart failure.

5. **Limitations of drug treatment**:
- At present, the main drug treatment method is diuretics, which are used to relieve the symptoms of peripheral right heart failure, but this cannot stop the progress of the disease.
- Other drugs, such as those that reduce pulmonary artery pressure or pulmonary vascular resistance, may also be considered for use, but these therapies should not delay the surgical timing for patients suitable for surgery.

In summary, this paper aims to explore the latest research progress in tricuspid valve diseases, especially the innovations in diagnosis, evaluation, and treatment, in order to improve the clinical management and prognosis of patients.